指南与共识瓣膜病与结构性心脏病

指南依从性对无症状重度主动脉瓣狭窄患者生存及不良临床事件的影响

Association of Guideline Adherence for Serial Evaluations With Survival and Adverse Clinical Events in Patients With Asymptomatic Severe Aortic Stenosis.
指南 / 共识 · JAMA Cardiol · 2017-01-01

该回顾性队列研究纳入300例无症状重度主动脉瓣狭窄患者,比较遵循指南每6-12个月定期评估与未遵循者的临床结局。遵循指南者主动脉瓣置换更频繁且更早,全因死亡和心衰住院风险更低,无死亡和心衰住院生存率更高,支持当前指南推荐。

要点

  • 遵循指南定期评估与更低的全因死亡和心衰住院风险相关。
  • 遵循指南者主动脉瓣置换率更高且时间更早。
  • 结果支持对无症状重度主动脉瓣狭窄患者进行密切监测。

核心结论

  • 研究支持对无症状重度主动脉瓣狭窄患者进行密切监测,并验证当前指南定期评估的推荐。
  • 指南依从性与更低的全因死亡和心衰住院风险独立相关。

研究设计与样本

  • 回顾性队列研究,纳入2007年7月25日至2012年12月6日在明尼阿波利斯心脏研究所门诊就诊的300例无症状重度主动脉瓣狭窄患者。
  • 比较遵循指南定期评估(每6-12个月)与未遵循者的临床结局,数据分析时间为2017年2月4日至7月10日。

主要发现

  • 遵循指南者(n=202)较未遵循者(n=98)主动脉瓣置换更频繁(54.0% vs 19.4%;P < .001)且中位时间更早(2.2 [1.2-3.6]年 vs 3.5 [2.0-5.8]年;P < .001)。
  • 未遵循者全因死亡风险更高(HR,1.57;95% CI,1.07-2.30;P < .001)。
  • 未遵循者心衰失代偿住院风险更高(HR,1.66;95% CI,1.27-2.18;P < .001)。
  • 遵循指南者4年无死亡和心衰住院生存率更高(38.7% vs 23.3%;P < .001),校正基线变量后差异仍显著(校正HR,1.54;95% CI,1.04-2.29;P = .03)。

关键数值与推荐

  • 当前指南经验性推荐对无症状重度主动脉瓣狭窄且左心室功能正常的患者每6至12个月进行定期评估。

临床怎么用

  • 临床中应对无症状重度主动脉瓣狭窄患者按指南每6-12个月定期评估,以提高指南依从性并改善预后。

局限性

  • 本研究为单中心回顾性队列研究,样本量300例,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with asymptomatic severe aortic stenosis and normal left ventricular function, current practice guidelines empirically recommend serial evaluations every 6 to 12 months. The benefit of this clinical monitoring is unknown. OBJECTIVE: To determine the association of guideline adherence with clinical outcomes in patients with asymptomatic severe aortic stenosis. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study involved 300 patients with asymptomatic severe aortic stenosis who were seen in the ambulatory Minneapolis Heart Institute at Abbott Northwestern Hospital. Rates of survival and adverse clinical events, including myocardial infarction, stroke, and heart failure hospitalization, were compared between patients who adhered to serial evaluation guidance and those who did not. Medical records were reviewed from July 25, 2007, to December 6, 2012. Data analysis took place from February 4, 2017, to July 10, 2017. MAIN OUTCOMES AND MEASURES: All-cause mortality, heart failure hospitalization, and major adverse clinical events during follow-up. RESULTS: The study population of 300 comprised 143 men (47.7%) and had a mean (SD) age of 78.6 (11.5) years. There were no differences in age, race/ethnicity, sex, comorbidities, insurance status, left ventricular function, and aortic stenosis severity between patients with (n = 202) and patients without (n = 98) guideline adherence. Aortic valve replacement (surgical or catheter based) was performed more frequently (54.0% vs 19.4%; P < .001) and the median (interquartile range) time for this performance was earlier (2.2 [1.2-3.6] years vs 3.5 [2.0-5.8] years; P < .001) in patients with guideline adherence. All-cause mortality was higher for nonadherent patients (hazard ratio [HR], 1.57; 95% CI, 1.07-2.30; P < .001), and these patients also had a higher rate of hospital admission for heart failure decompensation in follow-up (HR, 1.66; 95% CI, 1.27-2.18; P < .001). Four-year survival that is free from death and heart failure hospitalization was higher for adherent patients than for nonadherent patients (38.7% vs 23.3%; P < .001), and this difference remained significant in models adjusted for baseline variables (adjusted HR, 1.54; 95% CI, 1.04-2.29; P = .03). CONCLUSIONS AND RELEVANCE: The findings of this study support the need for close monitoring of patients with asymptomatic severe aortic stenosis and help to validate current guidelines for serial evaluations. These findings also support initiatives to improve guideline adherence in clinical practice.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ahmed A, Sorajja P, Garberich RF, et al. Association of Guideline Adherence for Serial Evaluations With Survival and Adverse Clinical Events in Patients With Asymptomatic Severe Aortic Stenosis. JAMA Cardiol. 2017. PMID: 28877303. doi:10.1001/jamacardio.2017.2952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。